Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

doi:10.1016/j.ejca.2019.12.003

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.

European journal of cancer (Oxford, England : 1990) - 1 Mar 2020

de Boo Leonora, Cimino-Mathews Ashley, Lubeck Yoni, Daletzakis Antonios, Opdam Mark, Sanders Joyce, Hooijberg Erik, van Rossum Annelot, Loncova Zuzana, Rieder Dietmar, Trajanoski Zlatko, Vollebergh Marieke, Sobral-Leite Marcelo, van de Vijver Koen, Broeks Annegien, van der Wiel Rianne, van Tinteren Harm, Linn Sabine, Horlings Hugo Mark, Kok Marleen

Abstract excerpt

BACKGROUND: The prognostic value of tumour-infiltrating lymphocytes (TILs) differs by breast cancer (BC) subtype. The aim of this study was to evaluate TILs in stage III BC in the context of BRCA1/2-like phenotypes and association with outcome and benefit of intensified platinum-based chemotherapy. PATIENTS AND METHODS: Patients participated in a randomised controlled trial of adjuvant intensified platinum-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ductal, Breast

Share to Carcinoma, Lobular

Share to Chemotherapy, Adjuvant

Share to Cyclophosphamide

Share to Epirubicin

Share to Lymphocytes, Tumor-Infiltrating

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed

Identifiers

PMID: 31956037
DOI: 10.1016/j.ejca.2019.12.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.PMID 31956037Read ↗

Impact of <i>BRCA</i> mutation status on tumor infiltrating lymphocytes (TILs), response to treatment, and prognosis in breast cancer patients treated with neoadjuvant chemotherapySemantic proximity Read ↗

Association between levels of tumor-infiltrating lymphocytes in different subtypes of primary breast tumors and prognostic outcomes: A meta-analysisSemantic proximity Read ↗

Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.Semantic proximity Read ↗

Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune SuppressionSemantic proximity Read ↗

Stromal Tumor-Infiltrating Lymphocytes Are Associated with Immune Checkpoint Protein Expression in Triple-Negative Breast Cancer Patients: A Subset of the Karachi PopulationSemantic proximity Read ↗

Should Tumor Infiltrating Lymphocyes, Androgen Receptor, and FOXA1 expression predict Clinical Outcome in Triple Negative Breast Cancer Patients?Semantic proximity Read ↗

Tailoring adjuvant chemotherapy regimens for patients with triple negative breast cancer.Semantic proximity Read ↗

Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysisSemantic proximity Read ↗

An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.Semantic proximity Read ↗

Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.Semantic proximity Read ↗

Molecular Characteristics of Lymphocyte-predominant Triple-negative Breast Cancer.Semantic proximity Read ↗

Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.